Combined recombinant humanized anti-PD-1 monoclonal antibody (JS']JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study.

被引：0
作者：
Cheng, Ke
Li, Zhiping
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Canc, Chengdu, Peoples R China
[2] West China Hosp, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16792
引用
收藏
页数：2
相关论文
共 50 条
[21]   Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS']JS001-ZS-BC001). [J].
Li, Wei ;
Yu, Yiyi ;
Xu, Xiaojing ;
Guo, Xi ;
Wang, Yueqi ;
Li, Qian ;
Wang, Yan ;
Cui, Yuehong ;
Liu, Houbao ;
Hao, Qing ;
Qu, Yueting ;
Huang, Lujia ;
Liu, Tianshu .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22]   Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study [J].
Chang, Chen ;
Li, Xiaofen ;
Cao, Dan .
BMC CANCER, 2021, 21 (01)
[23]   Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study [J].
Chen Chang ;
Xiaofen Li ;
Dan Cao .
BMC Cancer, 21
[24]   Phase III study (daNIS-2) of the antieTGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma [J].
O'Reilly, E. ;
Golan, T. ;
Ikeda, M. ;
Milella, M. ;
Taieb, J. ;
Wainberg, Z. ;
Wang, L. ;
Gyambibi, N. ;
Lopez, E. ;
Xu, K. ;
Macarulla, T. .
ANNALS OF ONCOLOGY, 2022, 33 :S254-S254
[25]   Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study [J].
Andrew, Dean ;
Ramesh, Ramanathan ;
Brooke, Belota ;
Bruce, Belanger ;
Deyaa, Adib ;
Eliel, Bayever ;
Chen Li-Tzong .
ANNALS OF ONCOLOGY, 2016, 27 :84-84
[26]   Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC). [J].
Park, Wungki ;
O'Reilly, Eileen Mary ;
Furuse, Junji ;
Kunieda, Futoshi ;
Jie, Fei ;
Kindler, Hedy L. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27]   Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study. [J].
Jiao Shun Chang ;
Bai Li ;
Dong Jiahong ;
Bai Chunmei ;
Hu Chunhong ;
Shen Liangfang ;
Qin Qun ;
Bai Yuxian ;
Fan Jia ;
Zang Aimin ;
Zhu Yanyun ;
Han Chun ;
Li Juan ;
Zhang Pengfei ;
Ye Sisi ;
Kang Xindan ;
Qiao Qian ;
Wang, Zhongmin Maxwell ;
Li Baiyong ;
Xia Yu .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[28]   An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update. [J].
Brezden, C. B. ;
Cantin, G. ;
Younus, J. ;
Panasci, L. C. ;
Klimo, P. ;
Laing, K. E. ;
Raymond, N. ;
Lam, W. ;
Trudeau, M. E. ;
Robidoux, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[29]   Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. [J].
Park, Wungki ;
O'Reilly, Eileen Mary ;
Furuse, Junji ;
Li, Chung-Pin ;
Oh, Do-Youn ;
Garcia-Carbonero, Rocio ;
Roth, Gael ;
Lee, Ho-Jin ;
Bhattacharya, Pranob P. ;
Moran, Diarmuid Martin ;
Yang, Jianning ;
Kunieda, Futoshi .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 :TPS782-TPS782
[30]   Zolbetuximab with gemcitabine plus nab-paclitaxel (GN) in first-line treatment of Claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study [J].
Park, W. ;
O'Reilly, E. M. ;
Li, C-P. ;
Oh, D-Y. ;
Garcia-Carbonero, R. ;
Roth, G. ;
Nakajima, T. ;
Moran, D. ;
Yang, J. ;
Li, R. ;
Kunieda, F. .
ANNALS OF ONCOLOGY, 2024, 35 :S934-S934
12345